What Scanda Treats: Main Uses and Benefits

Scanda is commonly used for managing internal parasite infestations, including livestock such as sheep and cattle that may have associated health challenges due to worm burdens. It provides therapeutic support to assist with parasite management, which may contribute to general well-being during symptomatic phases. These therapeutic domains are relevant for managing livestock health.

Easing Symptoms of Parasitic Infection

The medication is relevant for easing symptoms associated with internal parasite loads. This supportive relief helps manage conditions that interfere with animal growth and productivity and may assist with maintaining health consistency in affected herds or flocks.

Supporting Sustainable Parasite Management

The medication supports long-term parasite control. It provides ongoing support in the regulation of worm populations, helping maintain a sense of stability when symptoms of infestation are more noticeable. It is generally relevant for conditions characterized by periods of heightened symptoms that interfere with daily animal functioning.

---

Quick Fact: Relief for Internal Parasite Infestations

Regulatory References

1. European Medicines Agency therapeutic overview

Official Eligibility Rules for Scanda

The eligibility for Scanda (Liraglutide Injection) is strictly determined by regulatory criteria, defining populations where the medicine is either permitted, restricted, or absolutely prohibited.

Eligibility scope	Status (as stated in label)
Allowed Population (Adult)	Adults with BMI 30 kg/m^2, or BMI 27 kg/m^2 with 1 weight-related comorbidity.
Allowed Population (Pediatric)	Adolescents (aged 12 years) with body weight >60 kg and an initial BMI corresponding to 30 kg/m^2 for adults.

Contraindicated Populations	Absolute Exclusion Status
Thyroid/Endocrine History	Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Hypersensitivity	Prior serious hypersensitivity reaction to the active ingredient or excipients.
Pregnancy	Contraindicated for use during pregnancy.

Eligibility-related restrictions define additional limitations on use:

• Co-Therapy Exclusion: Must not be used concurrently with any other liraglutide-containing product or any other GLP-1 receptor agonist.
• Organ Impairment: Use is not recommended in patients with severe hepatic impairment, severe renal impairment/ESRD, or severe congestive heart failure (NYHA Class IV).
• Lactation: Use is not recommended while breastfeeding.

Regulatory documents establish that eligibility is strictly defined by meeting specific Body Mass Index and age criteria alongside the absence of absolute contraindications. The profile immediately excludes populations with certain thyroid and endocrine histories, while imposing “not recommended” limitations for use in severe organ impairment and during physiological states like pregnancy, based on official regulatory classifications.

Scanda Interactions with other medicines and products

Official regulatory documents describe a set of necessary restrictions and cautions regarding the co-administration of Scanda with other medicinal products. These restrictions are primarily based on the drug’s metabolic and transport characteristics, as well as its effect on blood clotting.

---

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Product Category	Official Regulatory Instruction	Mechanistic Basis
Combined P-gp and Strong CYP3A Inhibitors (e.g., certain azole antifungals, HIV protease inhibitors)	Avoid concomitant use.	Substantially increases Scanda exposure (via P-gp and CYP3A inhibition).
Combined P-gp and Strong CYP3A Inducers (e.g., rifampin, certain anticonvulsants, St. John's wort)	Avoid concomitant use.	Substantially decreases Scanda exposure (via P-gp and CYP3A induction).
Other Anticoagulants (e.g., unfractionated heparin, warfarin, dabigatran, apixaban)	Avoid concomitant use.	Additive pharmacodynamic effect on hemostasis.
Drugs Affecting Hemostasis (e.g., NSAIDs, aspirin, P2Y12 inhibitors, SSRIs, SNRIs)	Use with caution and monitoring.	Additive pharmacodynamic effect on hemostasis.

---

The regulatory profile strictly mandates avoidance of combining Scanda with strong dual inhibitors or strong dual inducers of the P-glycoprotein (P-gp) efflux transporter and the Cytochrome P450 3A (CYP3A) enzyme. These combinations significantly alter the concentration of Scanda in the body, which carries an increased risk of bleeding (inhibitors) or a potential loss of effectiveness (inducers). Co-administration with other major anticoagulants is also formally avoided due to the significantly heightened risk of hemorrhage. Caution is advised when used alongside medicines that impair platelet function or otherwise affect blood clotting, such as non-steroidal anti-inflammatory drugs (NSAIDs) or antiplatelet agents, requiring appropriate clinical monitoring.

The action of Scanda is achieved through a dual-mechanism approach that targets two fundamentally different, vital systems within the parasite by engaging non-overlapping pharmacodynamic pathways.

Rapid Parasite Neuromuscular Blockade

This domain describes the action of Levamisole, which functions as a cholinergic agonist of the parasite’s specific nicotinic acetylcholine receptors (nAChRs). By persistently activating these ion channels on the worm's muscle cells, the drug causes sustained depolarization and a resultant state of spastic paralysis. This physiological effect causes a rapid loss of the nematode's motor control, leading to the inability of the parasite to maintain its attachment or movement.

Cellular Structure Disruption and Metabolic Inhibition

This domain covers the mechanism of Oxfendazole, which acts as a polymerization inhibitor by binding to the parasite's beta-Tubulin protein. This molecular interference collapses the parasite's internal microtubular structure, crippling cellular transport and severely inhibiting the uptake of essential nutrients like glucose. The resulting physiological consequence is a progressive energy deficit and starvation that leads to cellular decay and the parasite's eventual inactivation.

Dual-Mechanism Advantage Against Resistance

The agents are combined to provide complementary, non-overlapping mechanisms of action. This strategy contributes to a broader mechanistic spectrum by engaging two non-cross-resistant pathways, which is relevant for the physiological management of multi-resistant parasite populations.

How to Use Scanda

The administration of Scanda (Levamisole/Oxfendazole Oral Drench) follows a standardized protocol. The medication is delivered exclusively via the oral route as a liquid drench suspension.

---

Dosing Principles and Preparation

The standard regimen requires calculating the dose volume based on the animal’s liveweight using a specific volume-to-weight ratio, commonly 1 mL per 10 kg liveweight. This volume delivers therapeutic concentrations of the active ingredients, such as Oxfendazole sim 5.0 mg/kg. A critical procedural step is that the suspension container must be shaken well immediately prior to drawing the dose. The dose must be accurately administered using specialized drenching equipment; animals should not be fasted before receiving the product. To ensure no animal is underdosed, the calculated volume for a group must be based on the weight of the heaviest animal.

---

Frequency and Population Rules

Scanda is intended for intermittent use, administered as a single treatment course rather than a continuous daily regimen. The decision for re-treatment is conditional, guided by an assessment of epidemiological factors, with subsequent use generally spaced at intervals of eight weeks or longer. Specific population restrictions apply: the product is prohibited for use in lambs under 20 kg and calves under 50 kg. Additionally, it is strictly forbidden for use in sheep or cattle producing milk intended for human consumption.

Research Evidence / Overview of Studies for Scanda

Evidence Supporting Use in Internal Parasite Management

Scanda, which is the dual combination of Levamisole and Oxfendazole, was studied in research exploring internal parasites, specifically roundworms (nematodes), in livestock. The core evidence base consists of controlled dose-confirmation trials, often referred to as Randomized Controlled Trials (RCTs), as well as Faecal Egg Count Reduction Tests (FECRTs). These studies monitored measurements related to gastrointestinal nematode burdens. The research examined how the measured outcomes for established infections compared to controls and whether changes were observed in the overall parasite burden.

Types of Studies and Measured Outcomes

The primary research designs used in research exploring the product’s measures involve short-term follow-up periods, typically lasting only a couple of weeks after the medicine is given. These studies were evaluated in controlled settings where researchers monitored measurements related to changes in parasite counts. The research highlights changes measured during the study period related to outcomes describing perceived discomfort or functional status. The evidence was observed in these specific study conditions.

Research Focus on Drug Resistance and Combination Strategy

Studies were conducted on populations presenting with internal parasitic infestations, particularly when those parasites may show resistance to traditional single-active medicines. Studies focusing on the combination strategy examined how the pairing of two chemically distinct active ingredients was associated with different measurements of parasite clearance compared to using either medicine alone. The combination approach was evaluated in settings involving known resistant parasite strains.

Extended Follow-up and Durability of Effect

The majority of efficacy research studies explored short-term changes, meaning that follow-up durations were limited to the period necessary to measure changes in parasite counts, typically 7 to 14 days. Consequently, long-term effects are not fully established in the core regulatory evidence. There is limited information for long-term outcomes related to the sustained prevention of re-infestation or the medication's impact on maintaining low parasite burdens over an extended season.

Evidence in Specific Livestock Populations

Scanda was evaluated in specific livestock groups, with the focus mainly on sheep (including lambs and ewes) and cattle (such as calves and beef cattle). The results apply only to the populations studied and reflect group patterns, not personal outcomes. Data for certain groups, particularly those with existing severe health issues, remain insufficient or limited.

Key Limitations and Research Gaps

One of the main research limitation frames is that while the initial measurements related to parasite clearance are described in controlled settings, the evidence quality is heterogeneous when comparing different real-world field conditions. Comparative evidence with other combination products is lacking in some areas. Evidence quality varies regarding the generalized outcomes across all geographical regions, as local parasite resistance patterns may drastically influence results.

Key Studies & References

1. Anthelmintic Dose Determination Studies for Levamisole and Oxfendazole against Ostertagia-type nematodes in deer (includes reference to Scanda in combination use)
2. Anthelmintic Resistance in Ruminants and Horses (WAAVP guidelines and background on combination strategy)
3. NADA 140-854: Freedom of Information Summary (FDA regulatory data for Oxfendazole efficacy and studies)

Common questions about Scanda (FAQ)

Q: What is the main condition Scanda is approved to treat?

A: Official documents describe Scanda as a dual combination anthelmintic product. It is approved for the treatment of internal parasitic infestations, specifically targeting various gastrointestinal and lung roundworms (nematodes) and certain tapeworms in livestock.

---

Q: How quickly should someone expect to see the effects of Scanda?

A: Studies have examined the onset of action for Scanda's ingredients. The Levamisole component works rapidly by causing paralysis of the parasite's motor control. Evidence indicates that the Levamisole component’s action is associated with an onset of effects within a few hours following administration as the body begins to clear the parasites.

---

Q: What are the most frequently reported mild side effects of Scanda?

A: According to official product information, adverse effects in treated animals are rare when the medication is used under specified conditions. Mild effects that have been reported include anorexia (loss of appetite) and unformed feces or diarrhea.

---

Q: What are the risks associated with taking Scanda during pregnancy?

A: Regulatory warnings contained within official Safety Data Sheets indicate that the formulation may damage the unborn child and may damage fertility. The official classification states that use in pregnant animals is generally not recommended due to limited safety data.

---

Q: How long does the body take to fully eliminate Scanda after the last dose?

A: The elimination of Scanda is defined by the necessary withdrawal period before the treated animal's meat or milk can be used for human consumption. This period is often around 21 days or longer for meat. The product is strictly prohibited for use in milk-producing animals intended for human consumption.

---

Q: Is Scanda used primarily to prevent or to manage symptoms?

A: Official documents indicate Scanda is primarily used as a treatment for animals with established internal parasitic infestations. Its efficacy includes activity against adult worms, immature larvae, and the arrested fourth stage (L4) larvae.

---

Q: Are serious allergic reactions to Scanda common?

A: Allergic reactions are a potential adverse effect, particularly when certain factors are present, such as high dosage of the Oxfendazole component. For handlers, the Levamisole component has been associated with serious blood disorders in a very small number of cases.

---

Q: Is it possible to take too much Scanda (signs of overdose)?

A: Yes, toxicity is possible if high dosages are administered. Official information describes that symptoms observed include cholinergic signs such as salivation, muscle tremors, lack of coordination (ataxia), increased urination and defecation, and eventual collapse.

---

Q: Are there known effects of Scanda on fertility?

A: Official Safety Data Sheets contain specific warnings regarding the formulation. Evidence indicates that the product may damage fertility based on laboratory studies.

---

Q: What type of medical monitoring (blood tests, etc.) might be necessary while taking Scanda?

A: The main monitoring requirement relates to the strict observance of the official withdrawal periods for meat and milk before these products can enter the human food chain. Additionally, official warnings describe restrictions against use in animals that are under severe stress or in poor nutritional condition.

---

Q: Is Scanda considered a high-risk medication?

A: Official documents describe that the therapeutic safety index for the Levamisole component is generally low compared to some other anthelmintics. This means the margin between the effective dose and a dose that could cause toxicity is relatively narrow.

---

Q: Does Scanda have a half-life, and what is it?

A: Yes, official pharmacokinetic data is available for the active ingredients. The Levamisole component has an estimated plasma half-life (t1/2) of approximately 3 hours in sheep, indicating it is rapidly eliminated. The Oxfendazole component is known to be eliminated over a longer period.

---

Q: Is it normal to have stomach upset when starting Scanda?

A: According to official product safety information, mild gastrointestinal effects are a possible adverse reaction. These may include anorexia (loss of appetite) and unformed feces or diarrhea.

---

Q: What medical conditions or factors prevent someone from using Scanda?

A: The product is strictly prohibited for use in sheep or cattle producing milk intended for human consumption. Official warnings describe restrictions against use in animals that are under severe stress or in poor nutritional or metabolic condition, as these factors may increase the risk of adverse effects.

---

Q: How is Scanda processed (metabolized) by the body?

A: Pharmacokinetic studies show that the Levamisole component is rapidly and extensively metabolized in the liver. This process involves pathways such as oxidation and hydrolysis, breaking the drug down into numerous metabolites. The drug and its breakdown products are then excreted primarily through the urine and feces.

---

Q: What non-prescription medicines or supplements interact with Scanda?

A: Official warnings specify a prohibition against co-administration of Scanda with other anticholinergic drugs, such as organophosphates. The official reason is that combining these medications can significantly increase the risk of toxicity.

---

Q: Are there specific food restrictions while using Scanda?

A: Regulatory instructions address the relationship between feeding and administration. Studies suggest that fasting or temporary feed restriction may impact the drug's absorption and efficacy, which is why official labeling notes the importance of the relationship between feeding and administration.

---

Q: Are there any studies regarding Scanda's use in children?

A: Regulatory documents impose specific restrictions based on the animal's weight and age, which limits use in young livestock. For example, official product information typically includes restrictions that prohibit the use of Scanda in young lambs and calves below specified weight thresholds.

Storage and Disposal Requirements for Scanda

Scanda (Levamisole/Oxfendazole Oral Drench) must be stored strictly according to regulatory labeling to maintain its stability. The product requires storage at Room Temperature (le 30 C) and must be protected from light and frost (do not freeze). Always store the product in its original, tightly closed container and, as a mandatory safety measure (P102/P405), keep it out of the reach of children and locked up.

---

Disposal

Disposal must align with local, state, and territory government regulations at an approved waste disposal plant. Release of the product into the environment is strictly prohibited; the medication is extremely toxic to aquatic species, meaning it must not contaminate waterways.